Hospital Universitari de Tarragona Joan XXIII -ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism

    Frontiers in Endocrinology, Vol. 15

  2. Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register

    Endocrine, Vol. 84, Núm. 2, pp. 683-693

  3. Risk factors for intraoperative hypertensive crisis in patients with pheochromocytomas and sympathetic paragangliomas

    Journal of Hypertension, Vol. 42, Núm. 2, pp. 252-259

2023

  1. An Integrated CT and MRI Imaging Model to Differentiate between Adrenal Adenomas and Pheochromocytomas

    Cancers, Vol. 15, Núm. 14

  2. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes

    Endocrine Connections, Vol. 12, Núm. 9

  3. Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY

    Journal of Endocrinological Investigation, Vol. 46, Núm. 4, pp. 805-814

  4. Genetic Study in Pheochromocytoma: Is It Possible to Stratify the Risk of Hereditary Pheochromocytoma?

    Neuroendocrinology, Vol. 113, Núm. 6, pp. 657-666

  5. Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas

    Frontiers in Endocrinology, Vol. 14

  6. Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry

    Journal of Endocrinological Investigation, Vol. 46, Núm. 11, pp. 2343-2352

  7. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas

    Endocrine-related cancer, Vol. 29, Núm. 12, pp. 645-655